BioCentury | Sep 13, 2018
Clinical News

BMS's IPF therapy discontinued after Phase II safety signal

...gained the product through its 2011 acquisition of Amira Pharmaceuticals Inc. for $325 million in cash (see "Amira...
BioCentury | Apr 11, 2017
Financial News

NASH newco Cirius raises $40M in series A

...all three were executives at cardiovascular company Laguna Pharmaceuticals Inc. Baltera was previously CEO of Amira Pharmaceuticals Inc....
BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

...inducing stem cell differentiation into myofibroblasts. BMS gained the molecule through its 2011 acquisition of Amira Pharmaceuticals Inc....
...antagonist IPF Ph II Study completed; timeline for data not disclosed Gained through acquisition of Amira Pharmaceuticals Inc....
BioCentury | Feb 18, 2015
Financial News

Laguna raises $30M in B round

...appointed as its new CEO former Amira Pharmaceuticals Inc. CEO Bob Baltera. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Amira...
BioCentury | Nov 4, 2013
Strategy

Teva blinks

...Levin acquired four companies - Kosan Biosciences Inc. , Medarex Inc. , ZymoGenetics Inc. and Amira Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Company News

Vital Therapies management update

...from CFO; he is succeeded by Michael Swanson who also becomes treasurer, formerly CFO of Amira Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Company News

Adheron board of directors update

...Inc. , Medford, Mass. Business: Autoimmune Appointed: Robert Baltera as executive chairman, formerly CEO of Amira Pharmaceuticals Inc....
BioCentury | Jan 7, 2013
Finance

Novo's public moves

...in cash. In 2011, Novo's notable exits included the sale of inflammation and fibrosis play Amira Pharmaceuticals Inc....
BioCentury | Nov 19, 2012
Strategy

Celgene's venture model

...record, coupled with Evans' reputation as a drug hunter and her time at inflammation company Amira Pharmaceuticals Inc....
...were two of Amira's co-founders. PharmAria COO Kevin Holme was executive director of development at Amira...
...responsible for developing asthma drug Singulair montelukast, a cysteinyl leukotriene receptor 1 (CysLT1) antagonist. At Amira...
BioCentury | Oct 22, 2012
Company News

Celgene, PharmAria deal

...funding to PharmAria, a company founded earlier this year by alumni from now-acquired inflammation company Amira Pharmaceuticals Inc....
...details. PharmAria's president, John Hutchinson, and CSO, Jilly Evans, were two of the co-founders of Amira...
...million up front plus up to $150 million in milestones. PharmAria COO Kevin Holme was Amira's...
Items per page:
1 - 10 of 67
BioCentury | Sep 13, 2018
Clinical News

BMS's IPF therapy discontinued after Phase II safety signal

...gained the product through its 2011 acquisition of Amira Pharmaceuticals Inc. for $325 million in cash (see "Amira...
BioCentury | Apr 11, 2017
Financial News

NASH newco Cirius raises $40M in series A

...all three were executives at cardiovascular company Laguna Pharmaceuticals Inc. Baltera was previously CEO of Amira Pharmaceuticals Inc....
BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

...inducing stem cell differentiation into myofibroblasts. BMS gained the molecule through its 2011 acquisition of Amira Pharmaceuticals Inc....
...antagonist IPF Ph II Study completed; timeline for data not disclosed Gained through acquisition of Amira Pharmaceuticals Inc....
BioCentury | Feb 18, 2015
Financial News

Laguna raises $30M in B round

...appointed as its new CEO former Amira Pharmaceuticals Inc. CEO Bob Baltera. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Amira...
BioCentury | Nov 4, 2013
Strategy

Teva blinks

...Levin acquired four companies - Kosan Biosciences Inc. , Medarex Inc. , ZymoGenetics Inc. and Amira Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Company News

Vital Therapies management update

...from CFO; he is succeeded by Michael Swanson who also becomes treasurer, formerly CFO of Amira Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Company News

Adheron board of directors update

...Inc. , Medford, Mass. Business: Autoimmune Appointed: Robert Baltera as executive chairman, formerly CEO of Amira Pharmaceuticals Inc....
BioCentury | Jan 7, 2013
Finance

Novo's public moves

...in cash. In 2011, Novo's notable exits included the sale of inflammation and fibrosis play Amira Pharmaceuticals Inc....
BioCentury | Nov 19, 2012
Strategy

Celgene's venture model

...record, coupled with Evans' reputation as a drug hunter and her time at inflammation company Amira Pharmaceuticals Inc....
...were two of Amira's co-founders. PharmAria COO Kevin Holme was executive director of development at Amira...
...responsible for developing asthma drug Singulair montelukast, a cysteinyl leukotriene receptor 1 (CysLT1) antagonist. At Amira...
BioCentury | Oct 22, 2012
Company News

Celgene, PharmAria deal

...funding to PharmAria, a company founded earlier this year by alumni from now-acquired inflammation company Amira Pharmaceuticals Inc....
...details. PharmAria's president, John Hutchinson, and CSO, Jilly Evans, were two of the co-founders of Amira...
...million up front plus up to $150 million in milestones. PharmAria COO Kevin Holme was Amira's...
Items per page:
1 - 10 of 67